Company: MYGN
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0000899923-25-000112
Chunk: 117

Company: MYRIAD GENETICS INC
Filing Date: 2025-11-04
Form: 10-Q
Item: Part I, Item 2
Chunk 117
---
 coverage decision will continue to negatively affect Pharmacogenomics revenue in future periods. 

23

Cost of Revenue

Three months ended September 30,(in millions)20252024Change% ChangeCost of revenue$61.9 $63.5 $(1.6)(3)%Cost of revenue as a % of total revenue30.1 %29.8 %

Cost of revenue for the three months ended September 30, 2025 decreased $1.6 million compared to the same period in the prior year primarily due to a reduction in the cost per test for the current period driven by reductions in the cost of laboratory reagents and supplies. 

Operating Expenses

Three months ended September 30,(in millions)20252024Change% ChangeResearch and development expense$28.2 $28.5 $(0.3)(1)%Sales and marketing expense$71.0 $69.9 $1.1 2 %General and administrative expense$67.9 $69.2 $(1.3)(2)%Total operating expenses$167.1 $167.6 $(0.5)— %Research and development expense as a % of total revenue13.7 %13.4 %Sales and marketing expense as a % of total revenue34.5 %32.8 %General and administrative expense as a % of total revenue33.0 %32.4 %Total operating expenses as a % of total revenue81.2 %78.6 %

For the three months ended September 30, 2025, operating expenses were relatively consistent with the expenses incurred in the same period of the prior year, reflecting stable operating activities across the business. We remain committed to disciplined cost management while maintaining investments in key strategic areas, such as research and development.

Goodwill and Long-lived Asset Impairment Charges

Three months ended September 30,Change(in millions)20252024% ChangeGoodwill and long-lived asset impairment charges$— $2.2 $(2.2)(100)%Goodwill and long-lived asset impairment charges as a % of total revenue— %1.0 %

There were no goodwill and long-lived asset impairment charges in the three months ended September 30, 2025.  In the prior year, we recognized $2.2 million of losses in connection with the sale of the EndoPredict business.

Other Income (Expense), Net

Three months ended September 30